Germany's Merck sells rights to Kuvan back to BioMarin Pharma
October 01, 2015 at 04:03 AM EDT
FRANKFURT, Oct 1 (Reuters) - Germany's Merck KGaA said it agreed to return to BioMarin Pharmaceutical Inc the rights to the Kuvan drug against rare genetic disorder PKU as it seeks to focus on cancer, immunology and neurology.